A preclinical study in post-menopausal bone loss mouse models found that CADD522, a small-molecule drug targeting RUNX2, protected against osteoporosis, prevented fat gain, and reversed some of the metabolic changes linked to menopause. The post Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice appeared first on GEN - Genetic Engineering and Biotechnology News .